Acrivon Therapeutics Reports Q2 2026 Financial Results

What Happened
Acrivon Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026 in a press release and filed a Current Report on Form 8-K on August 12, 2026. The 8-K furnished the press release as Exhibit 99.1 and the filing was signed by President and CEO Peter Blume-Jensen, M.D., Ph.D.

Key Details

• Filing: Form 8-K dated August 12, 2026 reporting results of operations and financial condition (Item 2.02).
• Period: Financial results cover the quarter ended June 30, 2026.
• Exhibit: Press release announcing the results is furnished as Exhibit 99.1 to the 8-K.
• Signature: Report signed by Peter Blume-Jensen, M.D., Ph.D., President and Chief Executive Officer.

Why It Matters
This 8-K notifies investors that Acrivon has publicly released its quarterly financial and business update; investors should read the press release (Exhibit 99.1) for the detailed revenue, expenses, cash position, and business developments that could affect the company’s outlook. The filing itself does not include the numeric results in the 8-K text; the press release is the primary source for the actual financial figures and operational updates.